

Beta-blockers, 248, 319
 in tachycardia, 380-381, 385
 Bifurcation diagrams, 276-277, 293
 Bigeminy, rule of, 313
 Blackman-Harris window, 185, 202
 Blood pressure, relationship between
 tachycardia rate and, 380-381
 Body surface mapping (BSM), 148-174
 history and technique of, 148-150
 in ischemia, 301-303
 of normal subjects, 150-153
 Boxcar filters, 346
 Breasts, imaging of, in perfusion scintigraphy,
 114
 Bruce protocol, 56
 BSM. *See* Body surface mapping
 Bundle branch blocks
 ECG and, 114, 132-140
 left
 body surface mapping in, 162-163
 as criterion for myocardial infarction,
 107
 ECG mapping of, 132
 perfusion scintigraphy and, 114
 pseudoprimary T wave changes and, 36-42,
 45
 QRS complex and, 26, 28
 right
 body surface mapping in, 161-162
 ECG mapping of, 132

C
 Calcium antagonists, 248
 Cardiac rate. *See* Heart rate
 Cardiac rhythms. *See* Rhythms
 Cardiomyopathy
 body surface mapping in, 161
 dilated, fractal geometry and mortality in,
 365
 PET as aid to ECG in, 88-89
 Carotid sinus massage (CSD), 381, 382
 CASS study, 59
 Catecholamines, 215
 Catheterization
 circadian variations investigated by,
 222-232
 electrode, 119
 for endocardial 12-lead ECG mapping,
 128-146
 for endocardial MAP recordings, 126
 single plane ventriculography during, 70
 Cathode-ray oscilloscope, 344
 Cells, cardiac, dynamics of excitation in
 models of, 281-297
 Cellular basis of cardiac arrhythmias,
 263-278
 Chagas disease, 243
 Chaos, definition of, 281

Chaos theory, 278, 354
 cardiac cells in terms of, 281-297
 Children, cardiac rhythm in, 355
 Circadian variations of electrical properties of
 heart, 222-232
 Circumflex artery disease, 72
 Clonidine, 216
 Cold pressor testing, in silent ischemia, PET
 studies and, 86-88
 "Common Standards for Quantitative
 Electrocardiography." *See* CSE
 study
 Computers
 CSE standardization project for ECG by,
 329-335
 diagnostic ECG programs for assessing
 performance, 335-340
 two types of logic, 350
 ECG data compression by, 350-351
 Fourier transform method by, 197
 future of ECG and, 308, 351, 370-376
 historical perspective on ECG and,
 343-351
 HRV analysis by, 235-244
 transmission-encoding-storage standards
 for ECG by, 339-340
 Conduction defects
 of atria, P waves and, 8-10
 body surface mapping in, 161-163
 high frequency components in, 199
See also Bundle branch blocks
 Conformance Testing Services (CTS),
 339-340
 Coronary arteriography
 body surface mapping correlated with,
 168-170
 perfusion status determined by, 110-111
 Coronary artery disease
 ambulatory monitoring of, 355
 chronic, perfusion scintigraphy in, 113-116
 predictive accuracy of ECG in, 72, 73
 stress studies in, 84-86
 ventricular late potentials in, 188
 Cor pulmonale, 69
 Coupling interval of the extrasystoles, 315,
 317
 CSD (carotid sinus massage), 381, 382
 CSE study, 329-340
 organizational structure of, 342
 CTS (Conformance Testing Services),
 339-340
 Cyclic AMP (cAMP), 218-219

D
 Data bases, 350-351, 370, 373-376
 Departure mapping, 156-158
 DFT (discrete Fourier transform), 197
 Diabetes, spectral analysis in, 241-242

Diagnosis, computer programs for
 assessing performance of, 335-340
 two types of logic, 350

Difference-equation model, 286-290

Difference maps, 154-157

Digital filters, 346, 348

Digitalis, 114, 274

Diltiazem, 248

Dipyridamole-induced myocardial ischemia,
 53-57

"Dome and dart" shaped waves, 14

Driving force, definition of, 264

Duchenne muscular dystrophy, PET studies
 as aid to ECG in, 88-89

Dynamical diseases, 278

Dipyridamole thallium scintigraphy, 114

Echocardiography

3D reconstruction of, 62-63

as aid to ECG in left ventricular diagnosis,
 61-65

MRI compared to, 95

Effective refractory period (ERP), in
 circadian studies, 223-225, 227, 228,
 232

Effector cell membranes, 214

Elderly people, cardiac rhythm in, 355

Electrical alternans of P waves, 8

Electrocardiography

advantages of, 305

ambulatory. *See* Holter recordings

future of, 308, 351, 370-376

high frequencies in

biophysical basis, 198-199

filters for elimination of, 344-345

as marker of vagal activity, 238-240

high resolution, 180, 197

history of, 24-26, 309, 329, 343-344

computerized electrocardiography,
 344-351

Holter recordings, 353

low frequencies in, as marker of
 sympathetic activity, 238-240

predecessors of, 24

recent expanded knowledge of, 305-306

sampling rates in, 345

signal averaging in. *See* Signal averaging

Electrophysiologic matrix

normal, 264-270

proarrhythmic, 271-274

Elema Mingograf 82 ink-jet recorder, 223

Endocardium

activation of, QRS pattern and, 136-140

ECG mapping of, 128-146

MAP recording of, 124-126

body surface mapping related to,
 172-174

Epicardium

activation of, QRS pattern and, 136-140

ECG mapping of, 128-146, 165

MAP recording of, body surface mapping
 related to, 172-174

Epinephrine, 215

ERP (effective refractory period), in circadian
 studies, 223-225, 227, 228, 232

European Community study. *See* CSE study

Excitability

abnormal, 274-278

altered, hypothesis of, 271-274

definitions of, 263

normal, 264-270

ventricular. *See*

Ventricles—excitation of

Exercise testing (stress testing)

in identifying high-risk myocardial

patients, 108-110

myocardial blood flow in, 85-86

noise in, 349, 350

perfusion scintigraphy as alternative to, 114

in silent ischemia, PET studies and, 86-88

in transient myocardial ischemia, 56, 57, 59

Extrasystoles, arrhythmias and, 314-320

F

Farey's rule, 282

Fascicular blocks

abnormal T waves in, 41

axis deviation and, 26-27

left anterior, IMI differentiated from,
 163-165

Fast-response tissues, 265

FDG (¹⁸F fluoro-2-deoxy-D-glucose), 79-86,
 88

FFTA. *See* Fourier transform analysis

Fibrillation

atrial

in paroxysmal supraventricular

tachycardia, 389-391

wavelength in prediction of, 300

ventricular

arrhythmogenic tissue and, 181

atropine and, 251

autonomic interactions and, 213

baroreflex sensitivity and risk of, 249

body surface mapping in, 165

ventricular late potentials in, 188

whether chaotic, 286-297

Filters

analog, 347-348

antialiasing, 345

band-pass, 348

boxcar, 346

digital, 346, 348

high pass, 197-198

- low pass, 346
- sophisticated linear phase response, 348
- Fourier transform, discrete (DFT), 197
- Fourier transform analysis (FFTA), 185-189, 197-201, 204-205, 236, 370-371
- Fractal geometry, 354, 362-365
- Frank XYZ leads, 330, 333, 334
- Frequency domain
 - autonomic interactions explored in, 238-244
 - Fourier transform pairs of signals in, 200-201
 - signal averaging in, 184-186
- F waves, 18-22

- GDP** (guanosine diphosphate), 218-219
- ¹³N-Glutamate, 86
- G proteins, 218, 219
- GTP (guanosine triphosphate), 218-219
- Guanosine diphosphate (GDP), 218-219
- Guanosine triphosphate (GTP), 218-219

- H**ear rate
 - arrhythmias and, 313-320
 - autonomic interactions and, 209-210
 - variability in (HRV)
 - in ambulatory monitoring, 357-362
 - autonomic nervous system and, 320-326
 - calculation of cycle lengths, 357
 - computer analysis, 235-244
 - indices related to autonomic tone, 354
 - malignant arrhythmias and, 250-251
 - mortality correlated with, 257-258
 - power spectrum analysis, 357
 - relationship to heart rate itself, 358-362

Heart transplant rejection, 357

Hemiblocks

- in coronary artery disease, 69
- use of term, 26

High pass filtering, 197-198

His bundle, 15, 180

His-Purkinje system

- body surface mapping in, 168
- in ventricular activation, 133, 140-141

Hodgkin-Huxley model, 291

Holter recordings

- arrhythmias and heart rate in, 33-34, 312-320, 326
- computer-assisted analysis of, 353-365
- heart rate variability in, 257-258
- history of, 353
- spectral analysis of, 237, 243
- sudden cardiac death and, 319-320

HRV. *See* Heart rate—variability in

Huffman encoding, 350

Hyperkalemia, 7

Hypertension, sympathovagal balance in, 240

Hypokalemia, 7, 278

Hypokinesia, 65

Idioventricular rhythms, 45

Impulse propagation, 269

Incremental updating, 350

Interatrial blocks, P waves and, 9-10

Interatrial septum, pacing of, 12

Inverse problem, 166-167

Ischemic heart disease

- antiarrhythmic drugs in, 247
- body surface mapping in, 301-303
- complex feedback in, 276
- cycle-length variability and mortality in, 357
- echocardiography in evaluation of, 61-65
- MRI in quantitative assessment of, 97-100
- parasympathetic activity and, 248-253
- perfusion scintigraphy in, 113-116
- prognostic value of ventricular arrhythmias in, 356-357
- silent, PET as aid to ECG in, 86-88
- sympathetic hyperactivity in, 247-248
- See also* Myocardial infarction; Transient myocardial ischemia
- Isoarea maps (isointegral maps), 151-155, 161, 170-171
- arrhythmic potential suggested by, 165-167
- Isometric projection maps, 152-153, 156
- Isopotential maps, 150-151, 153-154
- Isoproterenol, 212, 216

Kent's bundle, 15, 16

- in circadian experiment, 223-225, 227-232

LAD disease, 70-71

LAFB (left anterior fascicular block), IMI differentiated from, 163-165

Left anterior descending artery (LAD) disease, 70-71

"Lateral" leads, 72

Left atrium, pacing of, 12-15

Left ventricle

- hypertrophy of, 69
- body surface mapping in, 160-161
- mass of
 - body surface mapping and, 160-161
 - echocardiography and, 61-62
 - MRI determination of, 96-97, 104
 - wall thickening of, MRI in quantitative assessment of, 97-100
- See also* Tachycardia—ventricular; Ventricles
- Lidocaine, 248, 271-274
- Liminal length, 265, 269

- Linear phase response filters, 348
- Long QT syndrome (LQTS), 34, 124-126, 300
- Low pass filters, 346
- LQTS (long QT syndrome), 34, 124-126, 300

Magnetic resonance imaging (MRI), 371
 in left ventricular evaluation, 95-104

Mapping
 body surface. *See* Body surface mapping (BSM)

pace
 of atria, 10-15
 correlated with 12-lead ECG, 129
 of sites of origin of ventricular tachycardia, 128-146
 spectral, 187

MAPs. *See* Monophasic action potentials

Marquette Electronics, 31, 345, 348-350

Mayer waves, 235

MBR (modified Beeler and Reuter model), 291-293, 297

Median complex, 350

Medtronic 5325 stimulator, 223

Membrane conductance, definition of, 264

Metabolic disorders, P waves and, 7-8

Methacholine, 216

Methoxamine, 216

Mexiletine, 248

MILIS study, 107

Mitral stenosis P waves and, 7, 9

Mitral valve prolapse
 ambulatory monitoring of, 355-356
 cycle-length variability in, 357-358

Monophasic action potentials (MAPs), 119-126
 body surface mapping related to, 172-174

MRFIT (Multiple Risk Factor Intervention Trial), 59

Muscarinic agonists, 216, 253

Muscle artifact noise, 346

Muscular dystrophy, Duchenne, PET studies as aid to ECG in, 88-89

Myocardial infarction
 beta-blockers after, 381
 body surface mapping in, 153-158
 LAFB differentiated, 163-165
 echocardiography in estimation of size of, 63-65
 heart rate variability after, 255-260
 Holter recordings in prognosis of, 325-326
 MRI in quantitative assessment of, 97-99
 perfusion scintigraphy in, 107-113
 PET as aid to ECG in, 77-91
 P waves and, 6-7
 QRS complex and, 25, 27, 198
 Q-wave predictive accuracy in, 67-73, 77

- spectral analysis in, 240, 244
- survival for long period after, 192
- thrombolytic therapy for ECG accuracy and, 108
- perfusion scintigraphy and, 107, 110-113
- reperfusion in, 69, 110-113
- See also* Tachycardia—ventricular
- Myocardial ischemia, transient. *See* Transient myocardial ischemia
- Myocardial tissue tagging, 100-103, 371

Neuuropeptide Y, 214, 216-217

Nifedipine, 248

Nitroglycerin, 240

Noise reduction, 344-350
 in signal averaging, 182, 349-350

Norepinephrine (NE), 211, 213-218, 247

Obesity, conduction defects and, 8

Orthohypersympathicotony, 7

Oxotremorine, 253

PA interval, 8-9

¹¹C-Palmitate, 78-80, 82, 84-86, 88

Parasympathetic nervous system, malignant arrhythmias and, 247-260

Perfusion scintigraphy
 in identifying high-risk myocardial patients, 108-110
 as less accurate in women, 114
 in myocardial ischemia and infarction, 107-116

Pericarditis, P waves and, 5, 7

PES (programmed electrical stimulation), 223

Phenoxybenzamine, 248

Phentolamine, 217-218

Phenylephrine, 240, 249, 251-252, 256, 258

Plasminogen activator (rt-PA), 110, 112

Position of the heart in the thorax, P waves and, 4

Positron emission tomography (PET), 371
 as aid to ECG, 77-91
 in transient myocardial ischemia, 52, 54, 55

Posttachycardia syndrome, 41

Power line interference, 346

Power spectrum analysis, 357

Prazosin, 248

Precordial leads
 multiple, 26
 Q waves in, 71
 R-wave progression patterns in, 130
 standardization of, 344

Preeccitation, 41, 45, 307-308
 body surface mapping in, 165-167

PR interval, 9
 in CSE standardization study, 334

Procainamide, 124, 271
Programmed electrical stimulation (PES), 223
Propafenone, 248
Propranolol, 217–218, 248, 385–387
P-R segment, 180
 future analysis of, 372, 373
Pulmonary emphysema, 5
Purkinje fibers
 chaotic dynamics in, 282–286, 290
 excitability of, 212, 277, 278
 MAP recordings from, 121
P waves, 1–28
 in CSE standardization study, 331–334
 future analysis of, 372, 373
 in isopotential maps, 153, 154
 normal, 1
 transient factors influencing, 5–8
QRS complex, 24–28
 computer programs for detection of, 348–349
 in CSE standardization study, 331–334
 epicardial and endocardial activation and pattern of, 136–140
 frequencies of, 346
 future analysis of, 372, 373, 376
 higher frequency patterns of, 198–199
 isoarea maps for, 151–155, 161
 notches and slurs in, 197, 198, 201–202
 as pattern of ventricular activation, 128
 pseudoprimary T wave changes and, 37, 38, 41–47
 in signal averaging, 182–189
 spectral mapping, 197–199, 201–202, 204–206
 in ventricular repolarization, 31
 in ventricular tachycardia, 133–136, 142–143
 wide or narrow tachycardia, 307
QRST complex, isoarea maps for, 151–155, 165–167
QT interval
 in CSE standardization study, 334
 See Long QT syndrome; QX/QT ratio
Quinidine, 277
Q waves
 in myocardial infarction, 67–73, 77, 107, 158
 septal, during exercise, 57
 in ventricular tachycardia, 129
QX/QT ratio, 57
R
Real-time analysis, 353–354
Repolarization
 description of, 267

 drug effects on, 274–278
 ventricular, 31–34
Rhythms
 in ambulatory monitoring, 355–356
 chaos-theory interpretation of, 281–282
 as markers of functional states, 234–235
 See also Arrhythmias; Sinus rhythm
Right atrium, pacing of, 11–12
Right ventricle
 hypertrophy of, body surface mapping in, 158–160
 infarction of, 306–307
 pacing of, pseudoprimary T wave changes and, 38–42
 See also Ventricles
R-R interval, 235–243, 249, 257, 258
⁸²Rubidium, 78, 86–88
Rule of bigeminy, 313
RV pattern, 73
R waves
 in coronary artery disease, 72
 in ischemia, 301
 in myocardial infarction, 72
 poor progression of (PRWP), 71
 reversed progression of (RRWP), 71
 in sites of tachycardia origin, 129, 130
 in ventricular repolarization, 32
Saddle pattern, 151
Safety factor (for impulse propagation), 269
"Sawtooth" waves, 18
Signal averaging, 148, 180–192, 197–198, 370
 noise reduction in, 182, 349–350
 spectral mapping modification of, 187, 197–206
Signal conditioning, 346–348
Silver nitrate, 26
Single photon emission computed tomography (SPECT), 114
Sinus pauses in children, 355
Sinus rhythm
 two types of information in, 312–313
 variability of, 320–324
Slow response tissues, 267
Solid state recorders, 354
Sotalol, 124
SPECT (single photon emission computed tomography), 114
Spectral mapping and analysis, 187, 197–206, 236–243
Spectrotemporal map (STM), 201, 204–206
STM (spectrotemporal map), 201, 204–206
Stress testing. *See* Exercise testing
String galvanometer, 343–344
ST segment
 in ambulatory monitoring, 355

- baseline sway and, 347
 in coronary artery disease, 72
 exercise-induced changes in, 85–86, 115, 354
 in myocardial infarction, 107
 PET study, 81–82
 nonspecific changes in, 114
 in right ventricular infarction, 306–307
 spectral mapping of, 187, 198
 in thrombolytic therapy, 110–112
 in transient myocardial ischemia, 51–53, 56–59
 in unstable angina, 306
- ST-T waves**
 frequencies of, 346
 future analysis of, 372, 373, 376
 isoarea maps for, 151–155
 in transient myocardial ischemia, 58, 80
- Sudden cardiac death**
 baroreflex sensitivity and, 249
 beta blockers in prevention of, 319
 chaos theory and, 293
 complex arrhythmias as risk factor in, 356
 ECGs and prevention of, 244, 247
 QT prolongation and, 300
 ventricular late potentials in prognosis of, 190–192
- Supraventricular tachycardia. See Tachycardia—supraventricular**
- SVT. See Tachycardia—supraventricular**
- S waves, 26**
- Sympathetic nerves, interactions of, with vagal nerves, 209–219**
- Syncope, recurrent, ventricular late potentials in, 189–190**
- Syndrome x, 52, 58**
- Tachycardia**
 atrial, P waves and, 16–18
 autonomic-tone changes from, 378–392
 Gallavardin's, 41
 supraventricular (SVT)
 "aberration" used in, 26
 atrial fibrillation from, 389–391
 beta-blockers in, 381
 daily variability of, 222, 229–232
 pseudoprimary T wave changes in, 41–42
 spontaneous termination, 383–388
 ventricular
 body surface mapping in, 165–167
 discordant T waves caused by, 45
 ECG mapping of sites of origin of, 128–146
 from myocardial infarction, 180–181
 in normal elderly people, 355
 ventricular late potentials and, 187–192
 wide or narrow QRS, 307
 Technetium-99m isonitriles, 107, 111, 114
 Thallium-201 (^{201}Tl), 86, 107, 108, 113–115
 Threshold voltage, 265
 Time domain
 Fourier transform pairs of signals in, 200–201
 signal averaging in, 182–184
 Tocainide, 124, 125
 Transient myocardial ischemia
 ECG diagnosis of, 51–59
 sympathovagal balance in, 240–241
 Transmembrane action potentials (TAPs), 120–121
 Tricyclic antidepressants, P waves and, 7
 T waves, 24, 25
 concordant vs. discordant, 43–49
 in CSE standardization study, 331–334
 nonspecific changes in, 114
 postextrasystolic changes in, 41
 pseudoprimary changes in, causes of, 36–49
 simple classification of, 36
 in ventricular repolarization, 31
 T-U waves, 31
 Tyrode solution, 282
- U waves, 24**
 in transient myocardial ischemia, 57
- Vagal nerves**
 interactions of, with sympathetic nerves, 209–219
 stimulation of, in reducing arrhythmias, 249, 251
- Valsalva maneuver**
 P waves and, 5
 tachycardia termination by, 387–388
- Vectorcardiographic loops, 26**
- Ventricles**
 contractility of, autonomic interactions and, 210–211
 dysfunction of, and sudden cardiac death, 356–357
 excitation of
 autonomic interactions and, 212–213
 departure concept, 157–158
 isometric projection maps of, 152–154
 isopotential maps of, 150–151, 153–154
 hypertrophy of, 114
 QRS complex and, 27
 normal activation of, QRS complex and, 24–25, 198
 pacing of, 14
 preexcitation of, 41, 45, 307–308
 body surface mapping in, 165–167
 repolarization of, multidimensional quantitation of, 31–34
 See also Fibrillation; Left ventricle; Right ventricle; Tachycardia

- Ventricular extrasystoles (VEs), 42, 45
- Ventricular late potentials
 - pathophysiologic basis for, 180-182
 - prognostic significance of, 190-191
 - in recurrent syncope, 189-190
 - technical aspects of recording, 182-187, 197-198
 - in ventricular tachycardia, 187-189
- Ventricular premature complexes, fractal geometry of, 362-365
- Ventriculograms, body surface mapping correlated with, 168-170
- Verapamil, 248
- ¹⁵O-**Water**, 78
- Wavelength concept, 299-300
- Wenckebach conduction pattern, 181, 278
- Wilson terminal, 344
- Wolff-Parkinson-White syndrome
 - anatomical circuits in, 299
 - atrial pacing in patient with, 379-380
 - body surface mapping in, 166
 - ECG in evaluation of, 114
 - QRS complex and, 25, 28
 - supraventricular tachycardia transformed to fibrillation in, 389